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on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number
<4.0 signals/cell) cases
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BACKGROUND: The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group 2 tumours with
immunohistochemistry score 2+ and HER2/CEP17 ratio ≥2.0 and HER2 copy number <4.0 signals/cell were re-classified as HER2
negative. This study aims to examine the response of Group 2 tumours to neoadjuvant chemotherapy (NACT).
METHODS: 749 BC cases were identified from 11 institutions. The association between HER2 groups and pathological complete
response (pCR) was assessed.
RESULTS: 54% of immunohistochemistry HER2 positive (score 3+) BCs showed pCR, compared to 19% of immunohistochemistry
2+ FISH amplified cases. 27% of Group 2 treated with HER2 targeted therapy achieved pCR, compared to 19 and 11% in the
combined Groups 1+ 3 and Groups 4+ 5, respectively. No difference in pCR rates was identified between Group 2 and Group 1 or
combined Groups 1+ 3. However, Group 2 response rate was higher than Groups 4+ 5 (p= 0.017).
CONCLUSION: No difference in pCR was detected in tumours with a HER2/CEP17 ratio ≥2.0 and a HER2 score 2+ by IHC when
stratified by HER2 gene copy number. Our data suggest that ASCO/CAP HER2 Group 2 carcinomas should be evaluated further with
respect to eligibility for HER2 targeted therapy.
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BACKGROUND
Approximately 15–20% of newly diagnosed invasive breast
cancers (BC) show human epidermal growth factor receptor 2
(HER2) protein overexpression, usually due to HER2 gene
amplification.1–4 HER2 overexpression is associated with a worse
prognosis in patients who do not receive adjuvant systemic
therapy and is predictive of response to several systemic
therapies,5 in particular to HER2 targeted treatments.6–9 Hence,
eligibility criteria based on HER2 status have been developed to
optimise patient selection for these expensive and potentially
toxic targeted agents and have evolved over time.3,4,10
The early trials of trastuzumab in metastatic BC enrolled patients
with HER2 status defined using immunohistochemistry (IHC) assays
alone and considered both 3+ and 2+ IHC scores as eligible for
these trials.4,6,7,11 Subsequent analyses identified that only patients
with HER2 positive BC, defined as IHC 3+ reactivity and/or HER2 gene
amplification confirmed by fluorescent in situ hybridisation (FISH),
benefit from HER2 targeted therapies.6,7,12–14 The Food and Drug
Administration (FDA) definition of HER2 positivity was updated to
IHC 3+ or 2+ with HER2 gene amplification (defined as HER2/
chromosome enumeration probe 17 [CEP17] ratio ≥2.0, regardless of
the HER2 copy number).13,15,16 This definition was endorsed by the
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early HER2 guidelines in the United Kingdom (UK).17,18 Subsequent
guidelines by the American Society of Clinical Oncology (ASCO)/
College of American Pathologists (CAP) in 200710 and 20134 and the
further UK 2015 update19 expanded the definition of positivity to
include tumours with an average HER2 gene copy number
≥6 signals/nucleus regardless of the HER2/CEP17 ratio.
In 2018, ASCO/CAP published an update to refine the definition
of cases showing mismatch between the HER2/CEP17 ratio and
HER2 gene copy number, comprising ~4–15% of cases.3 Possible
combinations of the ratio and gene copy number were classified
into 5 groups (Table 1). Unlike Group 1 and Group 3, Group 2,
defined as a HER2/CEP17 ratio ≥2.0 with an average HER2 copy
number <4.0 signals per cell with IHC score of 2+, was re-classified
from HER2 positive4,19 to HER2 negative.3 This change was based
on the lack of substantive evidence for the efficacy of HER2-
targeted therapy in such tumours in terms of survival benefit.3,20
These tumours are rare. In a study of 4331 tumours with known
HER2/CEP17 ratio, HER2 copy number and HER2 IHC status, Press
et al.20 identified only 35 Group 2 tumours, of which only three
displayed an IHC 2+ score. Similar findings were observed by
Ballard et al., who found 1.4% of tumours fell in this group they
called ‘monosomy non-classical’ HER2 amplified BC cases (ratio ≥
2.0 with an average HER2 copy number <4.0 signals per cell).21 The
other two groups in their ‘non classical amplification category’
were designated as the ‘co-amplified group’ (ratio < 2.0, and
average HER2 copy number/cell ≥6.0) and a ‘low amplified group’
(ratio ≥ 2.0 and average HER2 copy number/cell 4.0–5.9) and
represented 0.8% and 2.1% of cases, respectively. The limited
number of patients with such tumours in the first generation of
adjuvant trastuzumab trials has been an obstacle to drawing
definitive conclusions regarding their response to HER2 targeted
therapy, and clinical data for this unusual category of cases are
desperately required.
In view of the low incidence of Group 2 tumours and the
difficulty in identifying sufficient numbers to demonstrate a
reliable survival benefit of targeted therapy, this study aimed to
assess the behaviour of these tumours in the neoadjuvant setting
as compared to the other well-defined groups, utilising a large
multi-institutional cohort. Complete pathological response (pCR)
to neoadjuvant therapy is a recognised surrogate for survival
outcomes and, when compared to definite HER2 positive (3+) and
HER2 negative (0/1+) groups, provides an indication of the
underlying biology of these tumours with respect to the HER2
pathway activation and response to anti-HER2 therapy.
METHODS
Study cohort
We analysed a retrospective cohort of 1374 BC patients who
received neoadjuvant chemotherapy (NACT), with or without
Table 1. Summary of the cohort including the distribution of the different HER2 groups and other variables.
Variables HER2 IHC defined Groups Total
No. (%)














No. (%) No. (%)
Total number 121 (16) 46 (6) 13 (2) 84 (11) 106 (14) 146 (20) 233 (31) 749 (100)
Tumour grade
1 1 (1) 1 (2) 1 (8) 2 (2) 3 (3) 2 (2) 1 (1) 11 (2)
2 63 (54) 25 (56) 5 (38) 39 (47) 69 (66) 83 (61) 130 (56) 414 (56)
3 53 (45) 19 (42) 7 (54) 42 (51) 32 (31) 52 (38) 100 (43) 305 (42)
Oestrogen receptor
Negative 26 (21) 12 (26) 0 (0) 16 (19) 26 (25) 64 (44) 113 (49) 257 (35)
Positive 95 (79) 34 (74) 13 (100) 68 (81) 80 (75) 81 (56) 118 (51) 489 (65)
HER2 targeted therapy given
No 13 (11) 5 (11) 5 (38) 84 (100) 106 (100) 8 (6) 233 (100) 454 (60)
Yes 108 (89) 41 (89) 8 (62) 0 (0) 0 (0) 130 (94) 0 (0) 295 (40)
Response to neoadjuvant therapy
No response 5 (4) 2 (4) 0 (0) 5 (6) 17 (16) 10 (7) 37 (16) 76 (10)
Partial response 94 (78) 32 (70) 12 (92) 70 (83) 77 (73) 57 (39) 147 (63) 489 (65)
Pathological complete
response
22 (18) 12 (26) 1 (8) 9 (11) 12 (11) 79 (54) 49 (21) 184 (25)
HER2 gene copy
number (Mean)
7.40 3.40 6.92 4.63 2.56 12.57 – –
Median (range) 7.6 (4.0–42.2) 3.4 (2.2–3.9) 6.5 (6.1–7.4) 4.6 (4.0–5.6) 2.6 (1.4-3.9) 10.8 (8.4–17.3) – –
CEP17 copy
number (mean)
2.14 1.48 4.33 3.13 1.98 2.93 – –
Median (range) 2.1 (1.2–5.7) 1.5 (1.0–1.9) 4.1 (3.2–5.5) 3.3 (2.2–4.9) 2.0 (1.2–12.3) 2.9 (2.6–3.5) – –
The cohort was classified into 5 categories (Group 1–5) for IHC 2+ cases according to the 2018 ASCO/CAP guideline as follows: Group 1 (IHC 2+, HER/CEP ratio
≥2.0; average HER2 gene copy number ≥4.0), Group 2 (IHC 2+, HER/CEP ratio ≥2.0; average copy number <4.0), Group 3 (IHC 2+, HER/CEP ratio <2.0; average
copy number ≥6.0), Group 4 (IHC 2+ HER/CEP ratio <2.0; average copy number 4.0–6.0), and Group 5 (IHC 2+, HER/CEP ratio <2.0; average HER2 gene copy
number <4.0). All tumours were selected from patients who received neoadjuvant therapy.
IHC immunohistochemistry.
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targeted therapy, and subsequent surgical resection in the years
2013–2019 from 11 institutions (Nottingham University Hospitals
NHS Trust; Addenbrookes Hospital, Cambridge; University Hospi-
tals Birmingham NHS Foundation Trust; University Hospitals of
Leicester NHS Trust; St. Vincent’s University Hospital, Dublin;
University Hospital Galway; St. Helens and Knowsley Teaching
Hospital NHS Trust, Liverpool; Guy’s and St. Thomas’ Hospital,
London; Ninewells Hospital, Dundee, Leeds Teaching Hospitals
NHS Trust, University of Turin, Italy). Inclusion criteria included
availability of data on HER2 gene copy number and HER2/CEP17
ratio, NACT and pathological response details with emphasis on
Group 2 tumours. As control groups, some cases with IHC scores of
HER2 3+ and 0/1+ were included (Table 1). Cases were identified
and data collected from all centres based on these defined criteria
to avoid sample bias.
Histological grade, details of oestrogen receptor (ER) status and
treatment regimen received were also collected. pCR was defined
as no residual invasive carcinoma in both the breast and axillary
lymph nodes regardless of the presence of residual ductal
carcinoma in situ (ypT0/is ypN0).23 All histopathological informa-
tion was obtained from the original pathology reports. Anon-
ymised data were analysed centrally. HER2 status was assessed
using IHC and ISH, as described in the UK guidelines,19
with primary IHC, followed by ISH on all borderline (2+) cases.
In cases with an unusual ISH pattern, such as the target study
cohort, the existing UK guidelines mandate counting 60 instead
of 20 cells. According to the IHC and ISH results, the tumours
were classified into the ASCO/CAP HER2 Groups3 (Table 1). ER
positivity were defined as nuclear staining of ≥1% of invasive
tumour cells.24
Patients were considered eligible for HER2 targeted therapies if
their tumours showed a HER2 IHC score of 3+, or 2+ with HER2/
CEP17 ratio ≥2.0 regardless of the HER2 copy number (i.e. ASCO/
CAP Groups 1 and 2) or if the HER2 copy number was ≥6 (Group
3). For subgroup analysis in this study, patients were categorised
according to HER2 status into (1) Groups 1, 2 and 3, and (2) Groups
4 and 5. Patients were subdivided into two groups based on the
type of neoadjuvant therapy received: (1) chemotherapy in
combination with HER2 targeted therapy, trastuzumab alone or
with either pertuzumab or lapatinib and (2) patients who received
chemotherapy only. Chemotherapy regimens given were in
accordance with individual unit protocols and included anthracy-
cline and taxane, anthracycline without taxane or non-
anthracycline based regimens.
This study was approved by the Nottingham Research Tissue
Bank Access Committee under the IRAS Project ID: 184265. Data
were collected as fully anonymised.
Statistical analysis
Statistical analysis was performed with SPSS (IBM SPSS Statistic,
Version 24.0). Associations between clinicopathological variables
and pCR were examined with Pearson Chi-square with Yates
correction (χ2) or Fisher’s exact tests, as appropriate. Bonferroni
correction for multiple testing was used to adjust p values.
Proportional odds logistic regression test was used to adjust
cofounders whenever needed. A two-tailed p-value < 0.05 was
considered statistically significant.
RESULTS
Of the informative cases, 749 patients received NACT, with or
without HER2 targeted therapy. This included 233 patients with
negative HER2 status (IHC score 0 or 1+), and 516 patients with a
HER2 IHC score of 2+ (n= 370) or 3+ (n= 146) (Table 1). There
was a strong correlation between positive HER2 status (IHC 3+
and FISH-amplified Groups 1, 2 and 3) and response to NACT (p <
0.0001) and this correlation was maintained on stratifying based
on ER status (p= 0.054 and p < 0.0001 in the ER negative and ER
positive groups, respectively). BC patients with HER2 IHC score of 3
+ achieved pCR in 54% of cases, compared to 19% of those with
IHC score of 2+ with FISH amplification (HER2/CEP17 ratio ≥2.0 or
HER2 gene copy number ≥6.0 (combined Groups 1, 2+ 3) (p <
0.0001) (Supplementary Table 1). The response to neoadjuvant
therapy in group 2 was independent of other histological and
treatment factors (Supplementary Table 2). This difference was
significant in the subgroup of women with ER positive BC who
received HER2 targeted therapy, here the IHC 3+ tumours showed
a pCR rate of 58% compared to 15% in the IHC 2+ FISH amplified
Groups (1, 2 and 3; 19/123) (p < 0.0001), but not in the ER negative
subgroup (pCR rate of 53% for IHC 3+ versus 38% IHC 2+
amplified, (p= 0.68)) (Table 2). The magnitude of benefit from the
addition of HER2 targeted therapy to chemotherapy was the same
in both HER2 positive groups (IHC 3+ and the IHC 2+ FISH
amplified) with a 2.3-fold increase in the pCR rate (24–56% and
9–21%, respectively) (Supplementary Table 1).
The ASCO/CAP Group 2 patients (n= 46) showed pCR in 26% of
tumours compared with 18% of those in Group 1 and 8% of those
in Group 3, respectively (both currently categorised as HER2
positive in the UK) (Table 1). There was no significant difference in
the response rate between Group 2 and Group 1 (p= 0.70) or
between Group 2 and combined Groups 1+ 3 (p= 0.58). Similar
results were identified when the cohorts were stratified according
to HER2 targeted therapy or ER status; the response rate in Group
2 was not different to Group 1 tumours (p= 0.575 and p= 0.375 in
the ER negative and ER positive cases, respectively) or combined
Group 1 and Group 3 tumours (p= 0.73 and p= 0.44 in the ER
negative and ER positive cases, respectively).
Group 2 tumours showed lower pCR rates compared to those in
the HER2 IHC 3+ group (p= 0.001). This difference was
maintained in the ER positive tumours (p < 0.0001) but not in ER
negative cases (p= 0.42). Although the response rate of Group 2
tumours was higher than that of the combined Groups 4 and 5
(p= 0.021), this difference was not evident when the cohort was
stratified based on ER status (p > 0.05). The pCR in patients with
HER2 negative tumours (IHC 0 or 1+) receiving NACT was 21%
(30% in ER negative and 13% in ER positive) compared with 27%
of patients in Group 2 receiving NACT and HER2 targeted
treatment (37% in ER negative and 20% in ER positive) (Table 2).
DISCUSSION
HER2 expression status is critical for selecting BC patients eligible
for HER2 targeted therapies. Currently, IHC and FISH are regarded
as equivalent assays for the assessment of HER2 status, due to
their high concordance rate. Approximately 15–30% of BCs are
IHC equivocal (2+), of which 15–30% are HER2 amplified. IHC 2+
amplified tumours comprise ~20–40% of HER2 positive
cases.3,22,25,26
HER2 protein, and not the gene amplification per se, drives BC
growth and progression, and is blocked using targeted agents.
Emerging evidence indicates that BC patients with strong protein
expression (IHC 3+) benefit to a greater extent than those with
gene amplification but with a borderline level of protein
expression (IHC 2+ amplified).27 IHC 3+ cases almost always
show high level gene amplification, whereas the IHC 2+ cases
often show low level amplification and/or heterogeneity.6,27–30
Response to NACT plus anti-HER2 targeted therapy occurs more
frequently in tumours with HER2/CEP17 ratios >3.7 and HER2 gene
copy number >11.5.28 In a study of HER2-targeted therapy without
chemotherapy, none of the 11 patients with HER2/CEP17 ratio <4.0
and/or HER2 gene copy number <10.0 achieved pCR, compared to
29% of patients with ratios >4 and/or HER2 copy number >10.31
Although some studies failed to demonstrate an association
between the degree of HER2 gene amplification and response to
adjuvant HER2 targeted therapies, the number of events in these
studies was low.20,29,32
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It is not surprising that BCs with bona fide HER2 positivity, as
evidenced by protein overexpression (IHC 3+) and/or high-level
gene amplification, are more dependent on HER2 to maintain
their malignant phenotype and are more responsive to HER2
targeted therapy. This is also reflected in studies looking at gene
expression analysis, with cancers belonging to the HER2-enriched
intrinsic subtype showing higher pCR rates and the patients
showing an improved event-free survival than those with non-
HER2-enriched tumours.33 Supporting this, and in line with our
results, Krystel-Whittemore et al. reported that BC with IHC 3+
HER2 protein over-expression showed significantly higher pCR
rate (67%) compared to BC with IHC 2+ and HER2 gene
amplification (17%).27
A variable level of response of HER2 positive BC to NACT (with
the same therapeutic agents) has been reported, with pCR rates
ranging from 23 to 70% in various studies.23,34,35 Although the
NACT pCR rate of the IHC 2+ BCs with evidence of HER2
amplification does not appear to differ from that of HER2 negative
cases (IHC 0/1+), which varies between 10 and 35%,23,34,36 the
magnitude of benefit from the addition of anti-HER2 targeted
therapy is more important. Our results indicate that both groups
(IHC 3+ and IHC 2+ FISH amplified) benefit from the addition of
anti-HER2 targeted therapy despite the difference in the overall
pCR rates achieved in each group. In clinical practice, categorisa-
tion of BC with equivocal protein expression (IHC 2+) but with
HER2 gene amplification remains a challenge. Determination of
the level, or pattern, of amplification associated with survival
benefits from anti-HER2 therapies remains to be defined. There is
an agreement that BC with HER2 gene copy number ≥6.0 are
categorised as HER2 positive and historically a ratio ≥2.0 alone was
used to define HER2 positivity regardless of the gene copy
number.10,17,19 However, there are tumours with HER2/CEP17 ratio
≥2.0 and HER2 copy number <6.0 and categorisation of these
cases is difficult due to their rarity and consequent lack of
Table 2. Degree of pathological response in subgroups based on HER2 targeted therapy and oestrogen receptor status.
Variables HER2 IHC defined groups Total
No. (%)
p-value Adjusted p value
(Bonferroni correction)





















HER2 Targeted therapy not offered
No response 2 (15) 0 (0) 0 (0) 5 (6) 17 (16) 1 (13) 37 (16) 62 (14) 0.003 0.009
Partial response 10 (77) 4 (80) 5 (100) 70 (83) 77 (73) 5 (63) 147 (63) 318 (70)
Pathological complete
response
1 (8) 1 (20) 0 (0) 9 (11) 12 (11) 2 (24) 49 (21) 74 (16)
HER2 Targeted therapy given
No response 3 (3) 2 (5) 0 (0) 0 (0) 0 (0) 9 (6) 0 (0) 14 (5) <0.0001 <0.0001
Partial response 84 (78) 28 (68) 7 (88) 0 (0) 0 (0) 52 (38) 0 (0) 171 (58)
Pathological complete
response
21 (19) 11 (27) 1 (12) 0 (0) 0 (0) 77 (56) 0 (0) 110 (37)
Oestrogen receptor negative
No response 1 (4) 0 (0) 0 (0) 2 (12) 3 (11) 4 (6) 21 (19) 31 (12) 0.030 0.054
Partial response 15 (58) 7 (58) 0 (0) 11 (69) 16 (62) 26 (41) 58 (51) 131 (52)
Pathological complete
response
10 (38) 5 (42) 0 (0) 3 (19) 7 (27) 34 (53) 34 (30) 93 (36)
Oestrogen receptor positive
No response 4 (4) 2 (6) 0 (0) 3 (4) 14 (18) 6 (7) 16 (14) 45 (9) <0.0001 <0.0001
Partial response 79 (83) 25 (73) 12 (92) 59 (87) 61 (76) 30 (37) 87 (74) 353 (72)
Pathological complete
response
12 (13) 7 (21) 1 (8) 6 (9) 5 (6) 45 (56) 15 (13) 91 (19)
HER2 targeted therapy treated cohort
Oestrogen receptor negative
No response 1 (4) 0 (0) 0 (0) – – 3 (5) – 4 (4)
Partial response 13 (57) 7 (63) 0 (0) – – 25 (42) – 45 (48) 0.281 0.680
Pathological complete
response
9 (39) 4 (37) 0 (0) – – 32 (53) – 45 (48)
Oestrogen receptor
positive
No response 2 (2) 2 (7) 0 (0) – – 6 (8) – 10 (5) <0.0001 <0.0001
Partial response 71 (84) 22 (73) 7 (87) – – 26 (34) – 126 (63)
Pathological complete
response
12 (14) 6 (20) 1 (13) – – 45 (58) – 64 (32)
IHC immunohistochemistry.
Significant p values are in bold.
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evidence on treatment efficacy. The latest ASCO/CAP guidelines
update published in 2018 re-classified these tumours into 2
groups: Group 1 (HER2/CEP17 ratio ≥2.0 and HER2 copy number
>4.0) remained as HER2 positive but Group 2 (ratio ≥ 2.0 and HER2
gene copy number <4.0) was changed to HER2 negative.
Applying the 2018 guidelines has resulted in an increase in the
proportion of HER2 negative cases compared with the 2013
classification.37–39 Evidence of pathological response in the
neoadjuvant setting as a surrogate end point for survival outcome
is a reasonable option, as we hypothesised in this study. Our
results show that both groups have an inferior pCR compared to
IHC 3+ but have a similar pCR rate to each other, which is slightly
higher than the pCR rate in HER2 negative cases receiving
chemotherapy alone. In a recent study by Wang et al.,40 there was
no significant difference between Group 2 (n= 30) and Group 1
(n= 100) tumours regarding the outcome in terms of disease-free
or overall survival in patients treated with or without targeted
therapy. These results are consistent with our study, which did not
find a difference in response rate to NACT and HER2 targeted
treatment between Group 2 and Group 1 or between Group 2 and
combined Groups 1 and 3. In the study of Perez et al. (n= 794),29
1.5% of cases with a ratio ≥2.0 were IHC 0/1+ and 10% were IHC 2
+ whereas 88.5% were classified as 3+ for HER2 IHC regardless of
the HER2 gene copy number; this supports the earlier concept that
cases with ratios ≥2.0 are typically HER2 positive. In the adjuvant
setting, Press et al.20 did not find a benefit from adjuvant
trastuzumab therapy in patients with Group 2 tumours. However,
92% of Group 2 patients in the study were classified as IHC 0 or
1+, which may explain the lack of benefit. In that study, the
distribution of HER2 IHC score (0/1+, 2+ or 3+) in tumours with
HER2 copy number <4.0 and those with ≥4.0–6.0 was similar
whereas the difference in the distribution was significantly
different between ratios <2 and ≥2.0 with 47% of cases with a
ratio ≥2.0 scored as 3+.20 Although 50% of cases with HER2 copy
number ≥6.0 scored 3+ this was observed only when the ratio
was ≥2.0 compared to 11% when the ratio was <2.0; further
emphasising the impact of the HER2/CEP17 ratios on HER2 protein
expression.20
Our study confirms that in patients with HER2 positive BC who
receive targeted therapy, ER status is important clinically. The best
response is seen in IHC 3+ tumours regardless of ER status, likely
reflecting the dominance of HER2 over the ER pathway. However,
in patients with HER2 positive tumours that are IHC 2+ amplified,
there is a significant impact of ER status on the response rate; 38%
pCR rate in ER negative tumours compared to 15% in ER positive
tumours, which may reflect the mixed effect of HER2 and ER
pathway activation on BC growth and progression.41–43 When the
analysis was limited to patients who had received chemotherapy
and HER2 targeted therapy and the cohort was stratified based on
ER expression, the response rate of Group 2 was not different to
that of Group 1 tumours or of the combined Group 1 and Group 3
tumours. Interestingly, in the subgroup of patients with ER positive
BC who received chemotherapy and HER2 targeted therapy, those
tumours that were IHC 3+ showed the highest pCR rate (58%)
compared to 14% in the IHC 2+/ISH amplified tumours (Groups 1
and 3) (or 15% if Group 2 was included; combined Groups 1, 2 and
3). In the ER negative subgroup of BC in women receiving
chemotherapy and HER2 targeted therapy the difference was less
marked (pCR rate of 53% for IHC 3+ versus 38% for IHC 2+/gene
amplified, respectively). This again highlights the importance of
making therapy decisions using both HER2 and ER status.
This study has some limitations. The number of cases in Group 2
was limited. The number of cases in Group 3 was also low (n= 9)
limiting reliable statistical analysis for this group. This has been a
limitation in other large studies, such as that of Press et al.20 in
which only one BC was classified as Group 3 with an IHC score of
2+. The number of cases with IHC 2+ and high-level gene
amplification was also limited, as might be expected. This may
explain the low pCR rate observed in Group 1 in this study.
However, the overall response rate of IHC 2+ amplified BC in our
study was in line with others27 using either the updated
guidelines3 (Groups 1+ 3) or the 2013 ASCO/CAP recommenda-
tions.44 In order to report on sufficient cases with these
uncommon patterns of HER2 expression, the cancers in this series
were collected from several centres. Although there are some
potential differences in disease stage and therapeutic regimens
adopted between centres, this reflects real world data and is, we
believe, therefore clinically relevant. Ideally, the data should be
collected as part of a prospective randomised trial. More
significantly, perhaps, no survival outcome measures could be
included in this multi-institutional retrospective study as patients
were treated in recent years without sufficient follow-up time; we
hope that this information will be collected prospectively.
In conclusion, the rate of pCR to NACT and HER2 targeted
treatment of BC that is HER2 IHC 3+ is higher than for tumours
that are IHC 2+ and HER2 amplified. The rates of pCR were
similar in the ASCO/CAP Group 1 and Group 2 tumours showing
score 2+ HER2 protein expression. Although our data does not
clearly refute the ASCO/CAP recommendation to exclude Group
2 from HER2 targeted therapy, it provides evidence that Group
2 with IHC score 2+ should be evaluated further with respect to
eligibility for HER2 targeted therapy. Further investigation,
including prospective randomised clinical trials of this group is
warranted.
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